Peptides and combination of peptides for use in immunotherapy against cancers
AssigneeImmatics Biotechnologies GmbH
InventorsToni Weinschenk, Oliver Schoor, Andrea Mahr
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsToni Weinschenk, Oliver Schoor, Andrea Mahr
Estimating the term…
The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that present a peptide consisting of the amino acid sequence of KIQEILTQV (SEQ ID NO:
Dependencies are inferred from the claim text.